C4 Therapeutics, Inc.
NASDAQ:CCCCBiotechnology
+$0.08 today
- Market cap
- $325.01M
- Beta
- 2.93
- P/E (TTM)
- -4.9
- EPS (TTM)
- -$0.82
Volume 2.75M
Average 2.76M
CCCC EPS (Diluted)
Earnings per share assuming conversion of dilutive securities such as options and convertible instruments.
C4 Therapeutics, Inc.NASDAQ: CCCC
EPS (Diluted) · Q1 FY2026 · quarter ended Mar 2026
EPS (Diluted) remains negative
Q1 FY2026 EPS (Diluted) was -$0.2, compared with -$0.37 a year earlier. Trailing-twelve-month EPS (Diluted) was -$1.19.
Context
- EPS (Diluted) grew in size in 1 of the last 3 fiscal years.
- FY2025 was the smallest annual figure in the 4 fiscal years shown.
What to watch
Whether EPS (Diluted) reaches the consensus estimate from 4 analysts of -$0.77 (+39.2%) for the fiscal year ending Dec 2026, a step up from the +16.4% reported in FY2025.
Sources:Income Statement Analyst consensus estimates Text generated from reported figures; not investment advice.
- Latest quarterMar 2026
- -$0.2-11.1% QoQ
- Last fiscal yearDec 2025
- -$1.27+16.4% YoY
- LTMMar 2026
- -$1.19+19.0% YoY
| Horizon | Past | Forecast | Difference |
|---|---|---|---|
| Quarter | +45.9% | +38.8% | -7.1 pp |
| 1 year | +16.4% | +39.2% | +22.8 pp |
| 3-year CAGR | — | — | — |
| 5-year CAGR | — | — | |
| 10-year CAGR | — | — |
Forecasts compare the consensus estimate with the latest reported period. Difference is forecast minus past, in percentage points.
EPS (Diluted) history
USD · from the income statement
- Latest · FY2025
- (1.27) USD
- Year-over-year change
- +16.4%
| Period | Period end | EPS (Diluted) | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | (1.27) | +16.4% |
| FY2024 | 2024-12-31 | (1.52) | +43.1% |
| FY2023 | 2023-12-31 | (2.67) | -1.9% |
| FY2022 | 2022-12-31 | (2.62) | -44.0% |
| FY2021 | 2021-12-31 | (1.82) | — |
EPS (Diluted) vs competitors
How CCCC compares with its peers on the latest reported figures
- Peers report in different currencies, so EPS (Diluted) is compared through growth and rates rather than absolute size.
- Its year-over-year change of +19.0% is the 5th highest of 9, against a peer median of +17.3%.
| Company | Period | LTM | YoY | 3-year CAGR |
|---|---|---|---|---|
| LTM Mar 2026 | -$0.37 USD | +63.0% | — | |
| LTM Mar 2026 | -$0.38 USD | +2.2% | — | |
| LTM Mar 2026 | -$0.46 USD | +20.7% | — | |
| LTM Mar 2026 | -$0.68 USD | +13.9% | — | |
| LTM Mar 2026 | -$1.19 USD | +19.0% | — | |
IMDXInsight Molecular Diagnostics Inc. | LTM Mar 2026 | -$1.51 USD | +57.1% | — |
| LTM Mar 2026 | -CHF 1.56 CHF | +9.3% | — | |
| LTM Mar 2026 | -$2.1 USD | +32.9% | — | |
| LTM Mar 2026 | -$7.77 USD | -1349.6% | — | |
| Peer median (excluding CCCC) | — | +17.3% | — | |
Competitors are the stored peer set for CCCC. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Income Statement
Metric | FY2021 Dec 2021 | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|---|
| Revenue | 45.79M | 31.1M | 20.76M | 35.58M | 35.95M |
| Cost of Revenue | 0 | 0 | 7.74M | 0 | 7.98M |
| Gross Profit | 45.79M | 31.1M | 13.02M | 35.58M | 27.97M |
| Gross Margin | 100.0% | 100.0% | 62.7% | 100.0% | 77.8% |
| Research & Development | 94.67M | 117.84M | 117.71M | 110.64M | 104.24M |
| Selling, General & Admin | 33.25M | 42.79M | 42.08M | 42.12M | 36.2M |
| Operating Expenses | 127.92M | 160.63M | 152.05M | 155.2M | 132.46M |
| Depreciation & Amortization | 1.49M | 1.68M | 7.74M | 1.82M | 1.96M |
| EBITDA | (80.26M) | (124.28M) | (122.1M) | (103.37M) | (102.91M) |
| EBITDA Margin | -175.3% | -399.7% | -588.3% | -290.5% | -286.3% |
| Operating Income | (82.13M) | (129.53M) | (139.03M) | (119.61M) | (104.49M) |
| Operating Margin | -179.4% | -416.6% | -669.8% | -336.1% | -290.7% |
| Interest Income | 387K | 3.58M | 9.81M | 14.43M | 10.35M |
| Interest Expense | 2.15M | 2.22M | 1.37M | 0 | 0 |
| Other Income / Expenses | (1.76M) | 1.36M | 7.82M | 14.43M | (384K) |
| Income Before Tax | (83.89M) | (128.18M) | (131.21M) | (105.19M) | (104.87M) |
| Pre-Tax Margin | -183.2% | -412.2% | -632.2% | -295.6% | -291.7% |
| Income Tax Expense | 0 | 0 | 1.28M | 131K | 121K |
| Net Income | (83.89M) | (128.18M) | (132.49M) | (105.32M) | (104.99M) |
| Net Margin | -183.2% | -412.2% | -638.3% | -296.0% | -292.1% |
| EPS (Basic) | (1.82) | (2.62) | (2.67) | (1.52) | (1.27) |
| EPS (Diluted) | (1.82) | (2.62) | (2.67) | (1.52) | (1.27) |
| Weighted Avg Shares | 46.04M | 48.86M | 49.64M | 69.37M | 82.89M |
| Weighted Avg Shares (Diluted) | 46.04M | 48.86M | 49.64M | 69.37M | 82.89M |
C4 Therapeutics, Inc.
NASDAQ:CCCC
Intrinsic Alpha fair value
Locked
Current Price
$2.48
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.